SCHEMBL249

SCHEMBL249

COC(=O)c1ccccc1-c1ccc(C)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.73
SLC6A4 P31645 3/20 0.73
SLC6A2 P23975 1/20 0.64
CYP46A1 Q9Y6A2 1/20 0.54
ROCK2 O75116 1/20 0.52
CSF1R P07333 1/20 0.52
KDR P35968 1/20 0.52
FLT3 P36888 1/20 0.52
GSK3A P49840 1/20 0.52
GSK3B P49841 1/20 0.52
CDK5 Q00535 1/20 0.52
ROCK1 Q13464 1/20 0.52
SLK Q9H2G2 1/20 0.52
IRAK4 Q9NWZ3 1/20 0.52
TSHR P16473 2/20 0.52
LMNA P02545 1/20 0.52
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 3/20 0.50
HSD17B10 Q99714 2/20 0.50
CFTR P13569 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10533851 0.94 SLC6A3 (0.65) SLC6A3SLC6A4SLC6A2CYP46A1ROCK2
SCHEMBL31316347 0.87 SLC6A3 (0.56) SLC6A3SLC6A4SLC6A2TSHRLMNA
SCHEMBL31318316 0.87 SLC6A3 (0.78) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
SCHEMBL27843639 0.87 SLC6A3 (0.74) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
SCHEMBL1775832 0.87 SLC6A3 (0.74) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
SCHEMBL68818 0.86 SLC6A3 (0.73) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
SCHEMBL8923988 0.86 SLC6A3 (0.73) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
Phosphine SCHEMBL11469830 0.85 SLC6A3 (0.72) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
SCHEMBL5700615 0.85 SLC6A3 (0.72) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
Bicarbonate SCHEMBL27467504 0.85 SLC6A3 (0.72) SLC6A3SLC6A4SLC6A2ROCK2CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115594589-A 4. A , Preparation method of (E) -methyl biphenyl-2-carboxylic acid methyl ester 济南大学(CN) 2023-01-13 CN claimed
CN-110372511-A Utilize the method for 4 '-methyl biphenyl -2- carboxylate methyl ester waste residues preparation high-purity 4 '-methyl biphenyl -2- carboxylate methyl ester 河南华商药业有限公司 2019-10-25 CN claimed
JP-9176103-A None JP disclosed
CN-114436833-B Preparation method of telmisartan key intermediate 4' -bromomethyl biphenyl-2-carboxylate 南京红太阳医药研究院有限公司 2024-12-24 CN disclosed
CN-115959962-A Visible light promoted halogenated alkane hydrodehalogenation method 中国科学院兰州化学物理研究所 2023-04-14 CN disclosed
CN-109311813-B Palladium-catalyzed meta-C-H functionalized universal ligands 斯克利普斯研究院 2023-02-28 CN disclosed
CN-115594589-A 4. A , Preparation method of (E) -methyl biphenyl-2-carboxylic acid methyl ester 济南大学(CN) 2023-01-13 CN disclosed
CN-115594589-A 4. A , Preparation method of (E) -methyl biphenyl-2-carboxylic acid methyl ester 济南大学(CN) 2023-01-13 CN disclosed
US-11485721-B2 Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut (DE) 2022-11-01 US disclosed
US-11485721-B2 Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut (DE) 2022-11-01 US disclosed
CN-114436833-A Preparation method of telmisartan key intermediate 4' -methylbiphenyl-2-carboxylic ester 南京红太阳医药研究院有限公司 2022-05-06 CN disclosed
EP-0453210-A2 Pyridine derivatives ZENECA LIMITED (GB) 1991-10-23 EP disclosed
WO-1991007404-A1 DIAZINE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-05-30 WO disclosed
EP-0420237-A1 Biphenylmethane derivative, the use of it and pharmacological compositions containing same Eisai Co., Ltd. (JP) 1991-04-03 EP disclosed
EP-0412848-A2 Quinoline derivatives, process for their preparation and their use as medicaments ZENECA LIMITED (GB) 1991-02-13 EP disclosed
EP-0399731-A1 Azaindenes ZENECA LIMITED (GB) 1990-11-28 EP disclosed
EP-0399732-A1 Benzimidazole derivatives ZENECA LIMITED (GB) 1990-11-28 EP disclosed
EP-0324377-A2 Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-19 EP disclosed
WO-1989006233-A1 ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-13 WO disclosed
EP-0253310-A2 Angiotensin II receptor blocking imidazoles E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11485721-B2 Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses CBR3, POR, CYP2F1 SLC6A3 2793/4885SLC6A4 3042/4885SLC6A2 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.